Article Text

Download PDFPDF
SENP1 activity sustains cancer stem cell in hypoxic HCC
  1. Alice Conigliaro1,2,
  2. Marco Tripodi1,
  3. Maurizio Parola3
  1. 1Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy
  2. 2Department of Biopathology and Medical Biotechnology, University of Palermo, Palermo, Italy
  3. 3Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
  1. Correspondence to Professor Marco Tripodi, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Via Regina Elena 324, Rome 00161, Italy; tripodi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hepatocellular carcinoma (HCC) represents the fifth most common cancer and the third leading cause of cancer mortality worldwide, with a minority of patients surviving at 5 years from diagnosis, despite treatment.1 HCC usually develops in conditions of chronic liver disease (CLD), mostly on the background of a cirrhotic liver, with liver transplantation at present being the only treatment strategy to cure both HCC and the specific CLD. All the other therapeutic strategies, because of the underlying liver cirrhosis, have to take into account, and may be limited in their feasibility, by the residual liver function of the individual patient, a critical parameter affecting the patient's prognosis.2 Indeed, even when the surgical intervention is feasible, according to current guidelines, efficient removal of the primary lesions is not often conclusive since intrahepatic recurrence, as well as extrahepatic metastasis, are very frequent and associated with poor prognosis for patients.3 Along these lines, current literature suggests that both the progression of CLD towards HCC development as well as HCC progression and acquisition of resistance to therapy are highly affected by the microenvironment, in which several cells (including tumour-associated macrophages or fibroblasts and cancer stem cells (CSCs)), inflammation, fibrosis as well as hypoxia, oxidative stress and autophagy are believed to play a critical role.4 In particular, hepatic hypoxia (ie, very common in CLD and HCC) and hypoxia-inducible factors (HIFs) are currently believed to be major determinant players that, in agreement with data in other tumours, can contribute to cancer development and progression by promoting and/or modulating transcriptional programmes (metabolic adaptation, …

View Full Text


  • Contributors AC, MP and MT wrote the commentary.

  • Funding Associazione Italiana per la Ricerca sul Cancro, airc 2016 IG_18843.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles